Verve Therapeutics, Inc. (VERV)

Verve Therapeutics, Inc. is a pioneering biotechnology company focused on transforming the treatment of cardiovascular disease through single-course gene editing therapies. Founded in 2018, the company aims to reduce the risk of heart disease by permanently turning off genes that are associated with high cholesterol levels. Verve's innovative approach centers on editing the genes in the liver to mimic naturally occurring genetic variants found in people with lifelong low cholesterol and reduced heart disease risk. The company is led by CEO Sekar Kathiresan, M.D., an esteemed physician-scientist with extensive expertise in cardiovascular genetics. Under his leadership, Verve is harnessing the power of cutting-edge gene editing technology to pave the way for breakthrough treatments in cardiovascular care. While revenue specifics may not be readily available, as a pioneering company still in a relatively early stage of development, Verve has garnered significant attention and investment from the biotech and healthcare sectors. Their work holds the promise of a revolutionary shift in how heart disease is treated and prevented.